Description
CYCLE Test P / Tren A (6 weeks)
Product intake:
- Take 3ml of Testosterone Propionate per week.
- Take 3ml of Trenbolone Acetate per week.
- Take Anastrazol 1mg (Arimidex) every 2 days
For end of cycle therapy:
- For recovery take Clomid 50mg per day for 20 days.
- For recovery take Nolvadex 20mg per day for 20 days.
Treatment schedule Dry mass gain P / Tren A test (6 weeks)
Week | Monday | Tuesday | Wednesday | Thursday | Friday | Open on Saturday | Sunday |
---|---|---|---|---|---|---|---|
Week 1 | 1ml Test P 1ml Tren A 1 Arimidex |
- | 1ml Test 1ml Tren A 1 Arimidex |
1ml Test P 1ml Tren A 1 Arimidex |
- | 1 Arimidex | |
Week 2 | 1ml Test P 1ml Tren A |
1 Arimidex | 1ml Test P 1ml Tren A |
1 Arimidex | 1ml Test P 1ml Tren A |
1 Arimidex | - |
Week 3 | 1ml Test P 1ml Tren A 1 Arimidex |
- | 1ml Test P 1ml Tren A 1 Arimidex |
1ml Test P 1ml Tren A 1 Arimidex |
- | 1 Arimidex | |
Week 4 | 1ml Test P 1ml Tren A |
1 Arimidex | 1ml Test P 1ml Tren A |
1 Arimidex | 1ml Test P 1ml Tren A |
1 Arimidex | |
Week 5 | 1ml Test P 1ml Tren A 1 Arimidex |
- | 1ml Test P 1ml Tren A 1 Arimidex |
1ml Test P 1ml Tren A 1 Arimidex |
- | 1 Arimidex | |
Week 6 | 1ml Test P 1ml Tren A |
1 Arimidex | 1ml Test P 1ml Tren A |
1 Arimidex | 1ml Test P 1ml Tren A |
1 Arimidex | - |
End of Cycle Therapy (PCT)
Week | Monday | Tuesday | Wednesday | Thursday | Friday | Open on Saturday | Sunday |
---|---|---|---|---|---|---|---|
Week 7 | 50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
Week 8 | 50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
Week 9 | 50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
50mg Clomid 20mg Nolvadex |
- |
Reviews
There are no reviews yet.